Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Sarilumab

"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"

Trial Locations (12)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Macquarie Park

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Vilnius

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY